23.3.2017 13:01 | Nasdaq OMX
XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board
AUSTIN, Texas, 2017-03-23 13:00 CET (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that that Dr. Dirk Arnold, a leading international specialist in gastrointestinal (GI) cancers, has joined the Company’s Scientific Advisory Board (SAB). Dr. Arnold will work with XBiotech to help navigate clinical development and communicate the findings for the Company’s lead product candidate in advanced colorectal cancer. Dr. Arnold’s main research interests include the treatment of GI cancers with a focus on targeted and immunotherapies, among others. Importantly, his special interest in clinical research methodologies and benefit evaluation are relevant to one of XBiotech’s lead oncology programs, which has involved the development of a novel measure of clinical efficacy in advanced cancer patients.
Dr. Arnold is amember of the following organizations: Executive Board of the European Society for Medical Oncology (ESMO) and European Cancer Organization (ECCO);chairman of Colorectal Cancer Study Group of the German Society of Clinical Oncology(AIO); American Society of Clinical Oncology (ASCO); Task Force Colorectal Cancer of the European Organization for Research and Treatment of Cancer (EORTC) GI study group; German Cancer Society; and the German Society of Haematology and Medical Oncology (DGHO). He is currentlyDirector of the Insituto CUF de Oncologia in Lisbon, Portugal.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visitwww.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Hminers18.8.2017 11:01 | pressemeddelelse
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs
Nasdaq17.8.2017 18:51 | pressemeddelelse
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market
Tetraphase Pharmaceuticals17.8.2017 14:31 | pressemeddelelse
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
RedHill Biopharma Ltd.17.8.2017 13:01 | pressemeddelelse
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
Safway Group16.8.2017 19:41 | pressemeddelelse
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV
Abeona Therapeutics Inc16.8.2017 15:39 | pressemeddelelse
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum